260 related articles for article (PubMed ID: 36835153)
21. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J; Holzmann C; Koczan D; Helmke BM; Bullerdiek J
Oncotarget; 2017 May; 8(21):34762-34772. PubMed ID: 28410233
[TBL] [Abstract][Full Text] [Related]
22. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
Mäkinen N; Heinonen HR; Moore S; Tomlinson IP; van der Spuy ZM; Aaltonen LA
Oncotarget; 2011 Dec; 2(12):966-9. PubMed ID: 22182697
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
24. Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.
Mäkinen N; Heinonen HR; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Br J Cancer; 2014 Apr; 110(9):2246-9. PubMed ID: 24642626
[TBL] [Abstract][Full Text] [Related]
25. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
26. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
27. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
28. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
29. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
Ravegnini G; Mariño-Enriquez A; Slater J; Eilers G; Wang Y; Zhu M; Nucci MR; George S; Angelini S; Raut CP; Fletcher JA
Mod Pathol; 2013 May; 26(5):743-9. PubMed ID: 23222489
[TBL] [Abstract][Full Text] [Related]
30. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
McGuire MM; Yatsenko A; Hoffner L; Jones M; Surti U; Rajkovic A
PLoS One; 2012; 7(3):e33251. PubMed ID: 22428002
[TBL] [Abstract][Full Text] [Related]
31. Racial differences in transcriptomics and reactive oxygen species burden in myometrium and leiomyoma.
Li Y; McNally RP; Feng Y; Kim JJ; Wei JJ
Hum Reprod; 2023 Apr; 38(4):609-620. PubMed ID: 36749068
[TBL] [Abstract][Full Text] [Related]
32. Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients.
Osinovskaya NS; Malysheva OV; Shved NY; Ivashchenko TE; Sultanov IY; Efimova OA; Yarmolinskaya MI; Bezhenar VF; Baranov VS
Int J Gynecol Pathol; 2016 Nov; 35(6):509-515. PubMed ID: 26630226
[TBL] [Abstract][Full Text] [Related]
33. High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.
Wang H; Ye J; Qian H; Zhou R; Jiang J; Ye L
Genet Test Mol Biomarkers; 2015 Mar; 19(3):162-6. PubMed ID: 25615570
[TBL] [Abstract][Full Text] [Related]
34. Catechol-O-methyltransferase Val158Met polymorphism is associated with increased risk of multiple uterine leiomyomas either positive or negative for
Dzhemlikhanova LK; Efimova OA; Osinovskaya NS; Parfenyev SE; Niauri DA; Sultanov IY; Malysheva OV; Pendina AA; Shved NY; Ivashchenko TE; Yarmolinskaya MI; Kakhiani MI; Gorovaya EA; Tkachenko AN; Baranov VS
J Clin Pathol; 2017 Mar; 70(3):233-236. PubMed ID: 27491313
[TBL] [Abstract][Full Text] [Related]
35. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
36. Screening of potential biomarkers in uterine leiomyomas disease via gene expression profiling analysis.
Liu X; Liu Y; Zhao J; Liu Y
Mol Med Rep; 2018 May; 17(5):6985-6996. PubMed ID: 29568968
[TBL] [Abstract][Full Text] [Related]
37. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
38. Single-cell sequencing reveals novel cellular heterogeneity in uterine leiomyomas.
Goad J; Rudolph J; Zandigohar M; Tae M; Dai Y; Wei JJ; Bulun SE; Chakravarti D; Rajkovic A
Hum Reprod; 2022 Sep; 37(10):2334-2349. PubMed ID: 36001050
[TBL] [Abstract][Full Text] [Related]
39. Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.
Moyo MB; Parker JB; Chakravarti D
Nat Commun; 2020 Feb; 11(1):1019. PubMed ID: 32094355
[TBL] [Abstract][Full Text] [Related]
40. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
